Modus Therapeutics Holding AB (publ) (STO:MODTX)
Sweden · Delayed Price · Currency is SEK 0.4310
-0.0150 (-3.36%)
Sep 4, 2026, 1:23 PM CET
STO:MODTX Balance Sheet
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 12.49 | 11.37 | 4.38 | 19.06 | 10.42 | 20.65 |
Cash & Short-Term Investments | 12.49 | 11.37 | 4.38 | 19.06 | 10.42 | 20.65 |
Cash Growth | - | 159.72% | -77.03% | 82.85% | -49.52% | 181.12% |
Other Receivables | 0.79 | 0.2 | 0.19 | 0.67 | 0.23 | 0.25 |
Receivables | 0.79 | 0.2 | 0.19 | 0.67 | 0.23 | 0.25 |
Prepaid Expenses | - | 1.12 | 0.26 | 0.26 | 0.57 | 0.24 |
Total Current Assets | 13.28 | 12.69 | 4.83 | 19.99 | 11.22 | 21.14 |
Other Long-Term Assets | - | - | 0.05 | 0.05 | 0.05 | 0.05 |
Total Assets | 13.28 | 12.69 | 4.88 | 20.04 | 11.27 | 21.19 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 0.65 | 2.27 | 1.56 | 1.31 | 1.36 | 4.49 |
Accrued Expenses | 2.19 | 0.62 | 0.49 | 0.53 | 0.86 | 0.83 |
Short-Term Debt | - | - | - | - | 11.5 | - |
Current Income Taxes Payable | - | - | - | - | 0.04 | - |
Other Current Liabilities | 0.2 | 0.72 | 0.71 | 0.52 | 0.1 | 0.14 |
Total Current Liabilities | 3.04 | 3.62 | 2.75 | 2.36 | 13.86 | 5.46 |
Other Long-Term Liabilities | - | - | - | - | - | -0 |
Total Liabilities | 3.04 | 3.62 | 2.75 | 2.36 | 13.86 | 5.46 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 8.92 | 7.3 | 2.16 | 2.16 | 0.97 | 0.97 |
Additional Paid-In Capital | 360.71 | 353.24 | 332.9 | 332.9 | 295.93 | 295.93 |
Retained Earnings | -359.39 | -351.46 | -332.92 | -317.37 | -299.48 | -281.16 |
Comprehensive Income & Other | - | - | 0 | - | - | 0 |
Shareholders' Equity | 10.24 | 9.07 | 2.14 | 17.68 | -2.59 | 15.74 |
Total Liabilities & Equity | 13.28 | 12.69 | 4.88 | 20.04 | 11.27 | 21.19 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | - | - | - | - | 11.5 | - |
Net Cash (Debt) | 12.49 | 11.37 | 4.38 | 19.06 | -1.08 | 20.65 |
Net Cash Growth | - | 159.72% | -77.03% | - | - | 181.12% |
Net Cash Per Share | 0.11 | 0.18 | 0.12 | 1.07 | -0.07 | 1.67 |
Filing Date Shares Outstanding | 148.7 | 121.63 | 35.94 | 35.94 | 16.1 | 16.1 |
Total Common Shares Outstanding | 148.7 | 121.63 | 35.94 | 35.94 | 16.1 | 16.1 |
Working Capital | 10.24 | 9.07 | 2.09 | 17.63 | -2.64 | 15.68 |
Book Value Per Share | 0.07 | 0.07 | 0.06 | 0.49 | -0.16 | 0.98 |
Tangible Book Value | 10.24 | 9.07 | 2.14 | 17.68 | -2.59 | 15.74 |
Tangible Book Value Per Share | 0.07 | 0.07 | 0.06 | 0.49 | -0.16 | 0.98 |